Atossa Therapeutics’ Expenses Jump 35% to $37.1M, Gains FDA Rare Disease Designations
Atossa Therapeutics reported 2025 operating expenses of $37.1 million, up from $27.6 million a year earlier, driven by a 50% increase in R&D spending to $21.2 million. The company secured FDA Rare Pediatric Disease and Orphan Drug designations for Z-endoxifen in Duchenne Muscular Dystrophy, unlocking potential Priority Review Voucher value.
1. Financial Performance
Atossa reported total operating expenses of $37.1 million for the year ended December 31, 2025, up from $27.6 million in 2024, reflecting increased investment as the company advances its clinical programs.
2. R&D Investment Breakdown
Research and development expenses rose 50% to $21.2 million, driven by $16.2 million in clinical and non-clinical trials (60% increase), $3.2 million in compensation (9% increase) and $1.8 million in professional fees (64% increase).
3. Regulatory & Clinical Advances
The company secured FDA Rare Pediatric Disease designation in December 2025 and Orphan Drug designation in January 2026 for Z-endoxifen in Duchenne Muscular Dystrophy, potentially generating a Priority Review Voucher valued at $100–$200 million; it also published peer-reviewed data on therapeutic mechanisms and won a precision endocrine therapy award.
4. Corporate Strategy & Leadership
Atossa strengthened its team by adding medical directors for breast oncology and rare diseases, aligned resources for potential commercialization, and maintains a strong balance sheet to pursue key clinical and regulatory milestones.